SPL

⚡ Flash Summary

Sitara Peroxide Limited (SPL) has applied for an extension to hold its Annual General Meeting (AGM) for the year ended June 30, 2025. The company cites a severe financial crisis leading to temporary suspension of operations and staff layoffs, causing delays in finalizing financial accounts and completing the audit. SPL requests a 30-day extension, pushing the AGM deadline to November 28, 2025, and has paid the required fee of PKR 15,000 for the extension application. The external auditor expects to complete the audit as soon as they receive the requested information, as of October 18, 2025.

📌 Key Takeaways

• 📅 SPL applied for an extension on October 28, 2025, to hold its AGM.
• ⏳ The extension is for 30 days, moving the deadline to November 28, 2025.
• 🏢 The application is made under Section 132 of the Companies Act, 2017.
• 🧾 The extension also covers the submission of annual accounts for the year ended June 30, 2025.
• 💸 SPL paid a fee of PKR 15,000 for the extension application (Challan No.M-2025-1930442).
• 📉 The company cites a ‘severe financial crisis’ as the reason for the delay.
• 🛑 SPL temporarily suspended operations and implemented staff layoffs as a cost-cutting measure.
• audit.
• 📄 A letter from the external auditors is attached, indicating delays in audit completion.
• 🗓️ The last AGM was held on September 01, 2025, for the financial year ended June 30, 2024.
• 🧾 The company is required to place its annual accounts before shareholders by October 28, 2025, as per Section 132.
• 🕒 The external auditor expects to complete the audit as soon as they receive necessary information (dated October 18, 2025).

🎯 Investment Thesis

Given the current financial difficulties, a HOLD rating is appropriate. Until the company stabilizes its financial position and completes the audit, investors should avoid further investment. A BUY recommendation could be considered if the company successfully restructures, improves profitability, and resumes normal operations. A SELL recommendation would be appropriate if the financial situation deteriorates further, leading to potential bankruptcy or significant losses. The price target would be based on future financial performance after restructuring.

⚡ Flash Summary

Sitara Peroxide Limited (SPL) reported its financial results for the first quarter ended September 30, 2024. Due to the complete closure of the plant for balancing, modernization, and replacement (BMR), the company experienced zero sales during the quarter, compared to PKR 15.868 million in the same period last year. Despite no revenue, the company managed to reduce its loss after tax to PKR 70.754 million from PKR 78.833 million in the corresponding period of the previous year, primarily through cost reduction and lower finance costs. The company awaits early BMR completion for viable operations.

📌 Key Takeaways

• 📉 Sales plummeted to zero due to plant closure for BMR.
• ❌ No revenue generated in Q1 2024 vs. PKR 15.868 million in Q1 2023.
• 💰 Cost of sales decreased to PKR 53.828 million from PKR 63.637 million.
• ⚠️ Gross loss stood at PKR 53.828 million.
• ➡️ Loss before tax improved slightly to PKR 81.453 million from PKR 78.595 million.
• ✅ Loss after tax reduced to PKR 70.754 million from PKR 78.833 million.
• 📉 Loss per share reduced to PKR 1.28 from PKR 1.43.
• ✔️ Depreciation decreased slightly from PKR 43.179 million to PKR 42.509 million.
• 📉 Finance costs decreased due to loan repayments.
• 👍 All expenses reduced by management.
• 🛠️ BMR is underway for viable operation.
• 🏦 Cash and bank balances increased to PKR 36.233 million from PKR 11.381 million at the beginning of the period.
• 📉 Revenue reserve shows accumulated loss of PKR 768.456 million.
• 👍 Net cash generated from operating activities is PKR 24.851 million compared to negative PKR 8.973 million last year.

🎯 Investment Thesis

Given the plant closure and ongoing BMR, a HOLD recommendation is appropriate. The company’s future prospects depend heavily on the successful completion of BMR and the resumption of profitable operations. Any potential BUY recommendation would depend on tangible progress on BMR and a clear timeline for resuming operations. Price target is speculative until operations resume.